The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
Source ↗
👁 0
💬 0
The post The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up? appeared first on 24/7 Wall St..
On August 25, 2026, Abbott Laboratories (NYSE:ABT) received FDA De Novo authorization for the Libre Duo 10 Day, the first wearable cleared to continuously monitor glucose and detect rising ketone levels that can precede diabetic ketoacidosis.
De Novo is the pathway the FDA uses for novel low-to-moderate-risk devices that have no existing predicate. It marks a regulatory
On August 25, 2026, Abbott Laboratories (NYSE:ABT) received FDA De Novo authorization for the Libre Duo 10 Day, the first wearable cleared to continuously monitor glucose and detect rising ketone levels that can precede diabetic ketoacidosis.
De Novo is the pathway the FDA uses for novel low-to-moderate-risk devices that have no existing predicate. It marks a regulatory
Comments (0)